The shrunken pore syndrome is associated with declined right ventricular systolic function in a heart failure population -the HARVEST study
Abstract
The close relationship between heart and kidney diseases was studied with respect to the "Shrunken pore syndrome" that is characterized by a difference in renal filtration between cystatin C and creatinine. Patients were retrieved from the HeARt and brain failure inVESTigation trail (HARVEST) which is an ongoing study undertaken in individuals hospitalized for the diagnosis of heart failure. Ninety-five of 116 patients who underwent transthoracic echocardiograms (TTE) were eligible for this study. We used four different formulas for estimated glomerular filtration rate (eGFR); CKDEPIcreatinine, CKD-EPI cystatin C , LMrev and CAPA. Presence of the syndrome was defined as eGFR cystatin C ≤ 60% of eGFR creatinine and absence of the syndrome as eGFR cystatin C >90% and <110% of eGFR creatinine. In a linear regression model, adjusted for age and sex, and the "Shrunken pore syndrome" defined by the equation pair CAPA and LMrev and the equation pair CKD-EPI cystatin C and CKD-EPIcreatinine , echocardiographic parameters were studied. The "Shrunken pore syndrome" showed statistically significant associations with measurements of right ventricular (RV) systolic function; (TAPSE and RV S´) (according to the equation pair CKD-EPI cystatin C and CKD-EPIcreatinine)
In conclusion, heart failure patients with the "Shrunken pore syndrome" are at increased risk of having RV systolic dysfunction whilst heart failure patients without "Shrunken pore syndrome" seem protected. These findings may indicate common pathophysiological events in the kidneys and the heart explaining the observed increased risk of mortality in subjects with the "Shrunken pore syndrome".
Introduction
Cystatin C has consequently been shown to be a more powerful risk marker of cardiovascular disease, hospitalization and death compared to creatinine [1, 2] , although the reasons behind these findings are yet poorly understood. One hypothesis for the supremacy of cystatin C as a risk marker is that an increase in cystatin C, with a molecular mass of 13343 Da, signals a shrinking of the pores in the glomerular membrane earlier than an increase in creatinine with a molecular mass of 113 Da.
Both creatinine and cystatin C are freely filtered over the healthy glomerular membrane. However, with increasing molecular masses the sieving coefficient for molecules is decreased. It has been observed in some cases that the filtration of cystatin C is less than for creatinine and it is hypothesized that this may be due to shrinking of the pores [3] . The "Shrunken pore syndrome" was recently suggested for the pathophysiologic state in patients characterized by an estimation of their glomerular filtration rate (GFR) based upon cystatin C, which is lower or equal to 60% of their estimated GFR (eGFR) based upon creatinine, i.e. when eGFR cystatin C ≤ 60% of eGFR creatinine [4] . Most recent data have identified the prevalence of the "Shrunken pore syndrome" to be associated with a significant rise in mortality in patients undergoing elective coronary artery bypass grafting (CABG) [5, 6] and heart catheterization [7] . The mechanism behind the increased mortality in this high-risk group is yet to be defined and although prevalent left ventricular (LV) systolic dysfunction was entered as a covariate in the multivariate Cox regression analysis in this study, no adjustment was done for right ventricular (RV) dysfunction, which indeed could have affected the observed long term association seen between the "Shrunken pore syndrome" and mortality. While chronic kidney disease (CKD) is an established predictor of poor survival in patients with heart failure (HF) [8, 9] , the pathophysiology of CKD in heart failure is complex. Traditional theories point at LV systolic dysfunction causing a decrease in arterial perfusion pressure and renal blood flow as the main source of renal dysfunction in patients with impaired cardiac output [10] . However, RV dysfunction has recently been associated with CKD (as measured by eGFR by the simplified Modification of Diet in Renal Disease (MDRD) formula)
as well as with a significant poorer survival in outpatients with chronic systolic HF.
These data suggest RV dysfunction to be one of the possible mechanistic links between HF and CKD [11] .
Therefore, in this study we aimed to examine if subjects with or without the "Shrunken pore syndrome" differed in risk of having cardiac dysfunction (e.g. RV dysfunction) as measured by echocardiographic imaging in a high risk HF population recruited from the ongoing HeARt and brain failure inVESTigation trail (HARVEST).
Materials
The HeARt and brain failure inVESTigation trail (HARVEST) is an ongoing study undertaken in individuals hospitalized for the diagnosis of HF in the city of Malmö, Sweden. The inclusion criteria for the HARVEST study are admission to medical or cardiology clinical for treatment under the diagnosis CHF (regardless if the CHF is chronic or newly discovered). The only exclusion criterion is the inability to deliver oral and written consent to the study. For patients with severe cognitive impairment, 
Methods
The re-examination included anthropometric measurements and blood samples drawn after overnight fast. Systolic (SBP) and diastolic (DBP) blood pressure was obtained after 10 minutes of rest in the supine position. Body mass index (BMI) was calculated as kg/m 2 . Body surface area (BSA) was calculated according to DuBois formula [12] .
Prevalent diabetes was defined as either self-reported physician diagnosis of type 2 diabetes or use of antidiabetic medication, or fasting plasma glucose ≥7 mmol/L.
Laboratory assays and GFR estimations
Measurements of creatinine and cystatin C were carried out at the Department of Clinical Chemistry, Skåne University Hospital in Malmö, participating in a national standardization and quality control system. The analyses were performed during November 2015. Plasma creatinine was measured using an enzymatic colorimetric assay with an IDMS-traceable calibrator on the Hitachi Modular P analysis system (Roche, Basel, Switzerland) [13] . The total analytical imprecision was 3.0% (with a concentration of 60 µmol/L in control sample) and 1.4% (with a concentration of 578 µmol/L in control sample; normal reference range: 60-100 µmol/L for men and 50-90 µmol/L for women). The plasma level of cystatin C was determined by an automated particle-based immunoassay, adjusted to the international reference preparation ERM-DA 471/IFCC [14] , using the Hitachi Modular P analysis system and reagents from DAKO (Dako A/S, Glostrup, Denmark). The total analytical imprecision was 2.1% (with concentration of 1.0 mg/L in control sample) and 1.7%
(with concentration of 4.0 mg/L in control sample.
The CAPA [14] and the CKD-EPI cystatin C [15] estimating equations, based on cystatin C, were used to estimate GFR. So were the LMrev [13] and CKD-EPIcreatinine [15] estimating equations based on creatinine. The best estimate of GFR is the mean of eGFRcystatin C and of eGFRcreatinine (eGFRmean) and this is true also when eGFRcystatin C and eGFRcreatinine differ significantly [13, [15] [16] [17] [18] . We used the eGFRmean to describe the renal function in the whole cohort.
Echocardiography
Conventional TTEs were obtained using an Philips IE33 (Philis, Andover, As all echocardiographic parameters were normally distributed the echocardiographic variables with significant association (p<0.05) with baseline shrunken pore status in the fully adjusted linear regressions according to model 2 were also tested with these variables dichotomized according to existing guidelines (i.e. tricuspid annular plane systolic excursion (TAPSE) < 16 mm and tricuspid anular systolic velocity (RV S´) < 10 cm/s) 18 . All analyses were performed using IBM SPSS Statistics version 23
(SPSS, Chicago, IL). All tests were 2-sided, whereby P< 0.05 was considered statistically significant.
Results

Study population characteristics
The study population is described in table I (study participants characteristics) and supplementary table I (echocardiographic variables).
The "Shrunken pore syndrome" was identified both by the equation pair CAPA and
LMrev and by the equation pair CKD-EPI cystatin C and CKD-EPIcreatinine in this study.
The definition of having or not having prevalent "Shrunken pore syndrome" was for both the CAPA/LMrev ratio and CKD-EPI cystatin C / CKD-EPIcreatinine ratios ≤0.6
(prevalent) and ratios >0.9 and <1.1 (not prevalent), respectively. Thus we identified 10 subjects with and 29 subjects without the "Shrunken pore syndrome" according to (Table II ).
In the fully adjusted linear regression analysis adjusted for model 2, measurements of RV systolic function; (TAPSE and RV S´) remained significantly associated with the "Shrunken pore syndrome" defined by the equation pair CKD-EPI cystatin C and CKDEPIcreatinine (Table III) . Thus, subjects with prevalent "Shrunken pore syndrome" were (Table III) . (Table IV) .
Discussion
The key finding of this study is that HF patients with "Shrunken pore syndrome" as defined by equation pair CKD-EPI cystatin C and CKD-EPIcreatinine are at increased risk of having RV systolic dysfunction whilst HF patients without "Shrunken pore syndrome" are protected from RV dysfunction.
The concept of the "Shrunken pore syndrome" was suggested from a recent study of 1349 consecutive patients, for which eGFR was requested at the Department of Clinical Chemistry [4] . To estimate GFR, both the LMrev-equation based upon creatinine, and the CAPA-equation based upon cystatin C, were used and the "Shrunken pore syndrome" was defined by eGFRcystatin C being less or equal to 60% of eGFRcreatinine in a patient [4] . In a most recent follow up study by Dardashti and coworkers, prevalence of the "Shrunken pore syndrome" was identified as an independent risk factor of increased mortality after CABG surgery after 3. systolic function (as measured as ejection fraction (EF%)) and prevalence of the "Shrunken pore syndrome" in either of the two definitions of the syndrome [5] . In concordance with these findings, in our study, prevalence of the "Shrunken pore syndrome" was not associated with LV systolic dysfunction (EF%) (Table II) .
Unfortunately, no comparable measurements for RV systolic function were accounted for in the study by Dardashti and coworkers [5] .
Although we found convincing associations between subjects with and without the Table II ). The reason behind this discrepancy of the two eGFR pairs is most likely due to the fact that CKD-EPIcreatinine results in a higher level than LMrev and thus more persons are defined as having the "Shrunken pore syndrome" with the pair CKD-EPIcystatin C and CKD-EPIcreatinine. However, this has to be further investigated in larger HF populations.
Attenuated LV systolic function and renal blood flow are strong factors of kidney dysfunction (e.g. GFR) in patients with chronic HF, so-called forward failure.
However, while decreased LV systolic function may contribute to decreased renal blood flow and decreased GFR in advanced HF, elevated renal venous pressure from backward failure due to RV dysfunction may also play an important and possibly earlier role in the pathophysiology of impaired renal function in chronic HF. This might explain our findings showing a significant association between the "Shrunken pore syndrome" and RV dysfunction, whilst no associations were seen for LV systolic dysfunction [21, 22] .
The association between the "Shrunken pore syndrome" and RV dysfunction may be part of the link between the heart and the kidneys, the so-called "Cardiorenal syndrome" [23] . We hypothesize that the difference in filtration fraction between cystatin C and creatinine in the glomerular membrane in those with the "Shrunken pore syndrome" may describe similar endothelial and structural changes in the coronary vessels and/or microcirculation of the myocardium as in the kidney. In the beginning of the pathophysiological process, affecting heart and kidneys, a narrowing of the pores in the endothelium may be a common pathway in both organs and part of the explanation for the cardiorenal syndrome. We can demonstrate that the renal function, based on eGFRmean from both creatinine and cystatin C, was similar between those without and with "Shrunken pore syndrome" indicating that the two groups did not differ in this respect.
Our study has both strengths and limitations. By consecutively including patients admitted to the hospital with the diagnosis of HF and no other exclusion criteria (except for not being able to give consent to the study) we have most likely mimicked a representative HF population. Also by adjusting for other known risk factors such as age, sex, diabetes status, BMI and systolic blood pressure, we believe that we illustrated that the "Shrunken pore syndrome" may have a role in RV dysfunction.
The HARVEST trial is conducted at a single regional center, which usually limits the applicability to other populations. However, a multi-center study would probably result in a greater inter-intra observer bias in echocardiographic measurements. As this is a cross-sectional study, it shares the inherent limitations about causality and control as all cross-sectional studies. Furthermore, our sample size was relatively small and despite significant associations, the results warrant replication in a larger cohort.
Finally, the study was undertaken in individuals of mainly Swedish descent, and the conclusions may not be generalizable to all ancestries.
Conclusion
Heart failure patients with "Shrunken pore syndrome" are at increased risk of having RV systolic dysfunction whilst HF patients without "Shrunken pore syndrome" seem protected. These findings might serve as a mechanistic explanation for the previously observed increased risk of mortality in subjects with the "Shrunken pore syndrome". The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
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